The alliance will leverage Inflammasome’s intravitreal (IVT) drug delivery technologies to develop compounds in Boehringer’s retinal disease pipeline portfolio.
ZyVersa announced advancements in development of our lead inflammasome inhibitor candidate, IC 100. IC 100 is a novel monoclonal antibody that inhibits the ASC component of multiple types of inflammasomes...